Prostate Cancer - Results from #340

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. October 14, 2024

Post-Treatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). October 14, 2024

Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate cancer. October 14, 2024

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). October 14, 2024

Detection of Germline Variants in Patients with Localized and Metastatic Prostate Cancer through Guideline-Based Testing. October 14, 2024

Methylation-based immune deconvolution in prostate cancer patients before and after radical prostatectomy. October 14, 2024

The Immune Microenvironment in Prostate Cancer: A Comprehensive Review. October 14, 2024

Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx October 11, 2024

Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics. October 11, 2024

Peripheral blood interferon responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipleucel-T. October 11, 2024

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. October 11, 2024

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy. October 11, 2024

Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. October 11, 2024

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead? October 11, 2024

Cone-Beam Computed Tomography (CBCT)-Based Online Adaptive Radiation Therapy (oART) for a Prostate Cancer Patient With Inflammatory Bowel Disease and Bilateral Total Hip Arthroplasty: A Case Report. October 11, 2024

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel October 11, 2024

Prostate cancer and solid organ transplantation: patient management and outcomes. October 11, 2024

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer. October 10, 2024

Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer. October 10, 2024

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. October 10, 2024

Page 18 of 1447